At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 170 enrolled
Drug / intervention
Comparator: MK-0773 +1 moredrug
Likely dose
Comparator: MK-0773 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IIa Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-0773 in Patients With Sarcopenia
In Brief
A Phase 2 clinical trial evaluating Comparator: MK-0773 and Comparator: Placebo for Sarcopenia. Completed, enrolled 170 participants.
Detailed Summary
A study to evaluate the safety, tolerability, and efficacy of MK-0773 in women with sarcopenia (loss of muscle mass).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSarcopenia
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 2007
Enrollment StartOct 2007
Primary CompletionOct 2009
TodayJul 2026
First PostedSep 14, 2007
Enrollment StartOct 1, 2007
Primary CompletionOct 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 18.8 years ago
Interventions
Comparator: MK-0773drug
MK-0773 50 mg tablets twice daily, 6 month treatment period
Comparator: Placebodrug
Placebo tablets twice daily, 6 month treatment period